The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity

被引:33
|
作者
Blanter, Julia B. [1 ]
Frishman, William H. [2 ]
机构
[1] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA
[2] Westchester Med Ctr, New York Med Coll, Dept Med, Valhalla, NY USA
关键词
cardiotoxicity; chemotherapy; beta-adrenergic blockers; angiotensin converting enzyme inhibitors; angiotensin receptor blockers; VENTRICULAR SYSTOLIC DYSFUNCTION; BREAST-CANCER; HEART-FAILURE; CARDIO-ONCOLOGY; DOXORUBICIN; CARVEDILOL; THERAPY; CANDESARTAN; ENALAPRIL; TRIAL;
D O I
10.1097/CRD.0000000000000252
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anthracycline (doxorubicin) and trastuzumab treatments for cancer patients have been known to cause cardiotoxicity. The current recommendations for prevention of cardiac events from cancer chemotherapies are largely based on opinion. The American Society of Clinical Oncology recommends active screening and prevention of modifiable cardiovascular risk factors. The risk factors are defined as tobacco use, high blood pressure, high cholesterol, alcohol use, obesity, and physical inactivity. Beta-adrenergic blockers and angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) have been the mainstay of treatment for heart failure patients with reduced left ventricular ejection fraction for many years. This review analyzed the use of beta-adrenergic blockers and ACE inhibitors/ARBs as protection against cardiomyopathy caused by anthracyclines and trastuzumab. Although many more studies are warranted, it was concluded that the addition of a beta-blocker early in the treatment of cancer patients who are undergoing anthracycline or trastuzumab treatment can have beneficial effects in preserving left ventricular ejection fraction and preventing chemotherapy-induced cardiotoxicity. The effects are more apparent in the short term. More studies of the long-term effects are warranted, as are the additive effects of using a beta-blocker and ACE inhibitor/ARB together to prevent chemotherapy-induced cardiotoxicity.
引用
收藏
页码:256 / 259
页数:4
相关论文
共 50 条
  • [21] Efficacy and safety of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for IgA nephropathy in children
    Vaz de Castro, Pedro Alves Soares
    Bitencourt, Leticia
    Pereira, Bruno Wilnes Simas
    Lima, Ananda Queiroz Rocha
    Hermida, Henrique Santos
    Moreira Neto, Carlos Roberto
    Mestriner, Mariana Dinamarco
    Simoes e Silva, Ana Cristina
    PEDIATRIC NEPHROLOGY, 2022, 37 (03) : 499 - 508
  • [22] Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure
    Chitnis, Abhishek S.
    Aparasu, Rajender R.
    Chen, Hua
    Kunik, Mark E.
    Schulz, Paul E.
    Johnson, Michael L.
    AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2016, 31 (05): : 395 - 404
  • [23] Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity
    Ohtani, Kisho
    Ide, Tomomi
    Hiasa, Ken-ichi
    Sakamoto, Ichiro
    Yamashita, Nami
    Kubo, Makoto
    Tsutsui, Hiroyuki
    CLINICAL RESEARCH IN CARDIOLOGY, 2019, 108 (10) : 1128 - 1139
  • [24] The Role of Angiotensin Receptor Blockers in Patients with Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema
    Beavers, Craig James
    Dunn, Steven P.
    Macaulay, Tracy E.
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (04) : 520 - 524
  • [25] Combined treatment with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: A review of the current evidence
    Tsouli, SG
    Liberopoulos, EN
    Kiortsis, DN
    Mikhailidis, DP
    Elisaf, MS
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2006, 11 (01) : 1 - 15
  • [26] Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension
    Weber, MA
    JOURNAL OF HYPERTENSION, 1997, 15 : S31 - S36
  • [27] Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on accumulation of aliskiren in the kidney
    Rahman, Asadur
    Ohmori, Koji
    Kohno, Masakazu
    Nishiyama, Akira
    JOURNAL OF HYPERTENSION, 2013, 31 (04) : 659 - 660
  • [28] Angiotensin II-receptor blockers: will they replace angiotensin-converting enzyme inhibitors in the treatment of hypertension?
    NM Kaplan
    Journal of Human Hypertension, 2000, 14 : S87 - S90
  • [29] Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19
    Xiao-Long Li
    Tao Li
    Qi-Cong Du
    Li Yang
    Kun-Lun He
    World Journal of Clinical Cases, 2021, 9 (20) : 5462 - 5469
  • [30] Penile angioedema associated with the use of angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers
    McCabe, John
    Stork, Christine
    Mailloux, Danielle
    Su, Mark
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2008, 65 (05) : 420 - 421